Epinephrine

A dry powder epinephrine delivered via a nasal spray yielded drug exposures that were equal to or higher than those achieved through autoinjector in a canine model, according to the results of a study performed by Belhaven Biopharma.

An epinephrine nasal spray is closer to approval in Europe, according to a press release from ARS Pharmaceuticals.

Patients with nasal congestion experienced enhanced absorption of epinephrine when it was administered via nasal spray compared with intramuscular administration, according to a study published in Annals of Allergy, Asthma & Immunology.

ARS Pharma recently announced that the FDA will likely rule on a new drug application for the company’s neffy epinephrine nasal spray — designed to treat type 1 allergic reactions such as anaphylaxis — by Oct. 2.

ARS Pharma has submitted a response letter to the FDA as it seeks approval for its neffy epinephrine nasal spray, which is designed to treat type I allergic reactions such as anaphylaxis, according to a company press release.

WASHINGTON — Most physicians believed that needle-free epinephrine delivery would be preferable among patients, and that it would lead to more patients carrying it and using it faster, survey results showed.

WASHINGTON — A nurse-led intervention improved pediatric food allergy knowledge, although it also revealed “concerning” shortcomings in certain areas of identification and management, research showed.

WASHINGTON — Four pooled studies noted similar pharmacodynamic performance for epinephrine delivered via nasal spray or autoinjector, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Epinephrine formulated as nasal powder demonstrated superior stability compared with autoinjector epinephrine, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.